ISSN: 1305-9327

 
 

VOLUME: 14 NUMBER: 3
 
 

Login | Register | Forgot Your Password?|



Online article submission system has been turned over to ScopeMed. We kindly request you to submit your current article or new articles via ScopeMed system
COPYRIGHT TRANSFERM FORM
AUTHOR FORM
ICMJE FORM
INFORMATION for AUTHORS
Print version of Medical Journal of Bakirkoy has been stopped as of 2018; the journal continues to be published as e-journal starting with March 2018 issue.

RSS Feed
 
 
12 - HER-2 Mutations in Non-Small Cell Lung Cancer
   
Erdem Sen, Guler Yavas, Ozlem Ata
   
  ABSTRACT
   
  Lung cancer is a heterogeneous and complex disease. Oncogenic driver mutations are critical for lung cancer development and serve as therapeutic targets. Oncogenic driver mutations are well defined in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and reactive oxygen species-1 (ROS-1) mutations. Human epidermal growth factor receptor-2 (HER-2) positivity and anti-HER-2 treatments are well studied in breast cancer. In non-small cell lung cancer (NSCLC), these treatment approaches are under investigation. In NSCLC, mutations of HER-2 are found in 2%–4% of cases. The most commonly encountered mutations are frame insertions in exon 20. There is no evident association between HER-2 amplification and HER-2 mutations. HER-2-targeted therapy needs further clinical investigations in NSCLC.
   
  Keywords
  HER-2 mutations, non-small cell lung cancer, HER-2 targeted therapy
   
  To download fulltext click here